AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06193642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental
Description: Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
Study NCT05423314 — intervention group
Intervention type: PROCEDURE
Intervention: knee brace cold therapy
Description: receiving a knee brace cold therapy to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase.
Study NCT05309902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablet.
Study NCT05437731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coated titanium mesh
Description: patients will undergo repairing of defects or reconstruction using the titanium mesh coated with hydroxyapatite nanocrystals.
Study NCT05437731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uncoated titanium mesh
Description: patients will undergo reconstruction using the conventional uncoated titanium mesh.
Study NCT06364007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+STRIDE+Len
Description: patients will be administrated with STRIDE plus lenvatinib (8 mg or 12 mg) once daily plus HAIC- modified FOLFOX (oxaliplatin, 85 mg/m2; leucovorin, 400 mg/m2; 5-fluorouracil bolus, 400 mg/m2 on day 1; 5-fluorouracil infusion, 2400 mg/m2 for 46 h).
Study NCT05448469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spinae plane block
Description: patients will receive combined general anesthesia and ultrasound guided erector spinae plane block with 20 ml of bupivacaine 0.2 % at T9 level bilaterally.
Study NCT05448469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided paravertebral block
Description: patients will receive combined general anesthesia and ultrasound guided paravertebral block with 7 ml of bupivacaine 0.2 % at T8 and T10 bilaterally.
Study NCT05448469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional analgesia
Description: patients will receive combined general anesthesia and conventional analgesia
Study NCT00246675 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Frusemide
Study NCT05309902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soticlestat placebo-matching tablet.
Study NCT06046404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed reduction
Description: the intervention of closed fracture reduction widely known and part of daily practice. we test the eficacy of this intervention by not performing it in our test group.
Study NCT06046404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no closed reduction
Description: no reduction will be performed
Study NCT05679193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily
Study NCT05679193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol capsules 20mg taken orally.~Day: 1-3:~20mg twice daily~Day: 4-19 (25 , In cases of delayed RALP an extension of up to 6 days is allowed.in cases of delayed surgery).~2x 20mg twice daily~Day 20-22 20mg twice daily
Study NCT04666935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program
Description: Sport Injury Prevention Program.
Study NCT04666935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm up
Description: Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
Study NCT05309902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin over-encapsulated tablet.
Study NCT06361368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS150
Description: Participants took one capsule with PS150 after dinner for 30 days.
Study NCT05309902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Moxifloxacin placebo-matching capsule.
Study NCT06361368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants took one capsule with placebo after dinner for 30 days.
Study NCT05785182 — intervention group
Intervention type: PROCEDURE
Intervention: Open Fracture
Description: Patients 18 years of age or older with open fracture. Provision of informed consent.
Study NCT05785182 — intervention group
Intervention type: PROCEDURE
Intervention: Infected Fracture
Description: Patients 18 years of age or older with infected fracture. Provision of informed consent.
Study NCT05324384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study NCT05324384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Use of different doses of the same drug
Study NCT05567302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present.
Study NCT05567302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myofascial release
Description: The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
Study NCT05952102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil capsule
Description: Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Study NCT05659199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave
Description: Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
Study NCT05659199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
Study NCT05577559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intermediate cervical plexus block
Description: patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
Study NCT05577559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Erector spinae block
Description: patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
Study NCT04150419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Attentional training to avoid threatening, negative or pain-related information.
Study NCT04150419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Attention training for vigilance for positive emotional information.
Study NCT05761314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular characterization of solid tumor in RASopathies
Description: NGS analysis on tumor sample
Study NCT06578390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneal device
Description: Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
Study NCT04586673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1 (C1)
Description: ChAdOx1.tHIVconsv1 5 x 10\^9 vp
Study NCT04586673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1 (C1)
Description: ChAdOx1.tHIVconsv1 5 x 10\^10 vp
Study NCT04586673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3 (M3)
Description: MVA.tHIVconsv3 1 x 10\^8 pfu
Study NCT04586673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4 (M4)
Description: MVA.tHIVconsv4 09. x 10\^8 pfu
Study NCT04939298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
Study NCT05056116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Toripalimab
Description: Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
Study NCT05866614 — intervention group
Intervention type: DRUG
Intervention: Remsima IV
Description: Patient will be treated with Remsima IV as per the SmPC or
Study NCT05866614 — intervention group
Intervention type: DRUG
Intervention: Remsima SC
Description: Patient will be treated with Remsima SC as per the SmPC
Study NCT05287581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVES
Description: The experimental intervention is a 16-week progressive home-based exercise program in which participants are supported through seven coaching calls based on social cognitive theory and motivational interviewing principles. The individual sessions will provide tailored support for increasing physical activity behavior towards the recommended guidelines of at least 150 minutes of moderate aerobic activity and two strength-training sessions per week. There are no drugs involved in the intervention.
Study NCT05102162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime, Meropenem, or Piperacillin/Tazobactam
Description: A 1:1 randomization scheme based on the infusion duration (continuous over 24 hours or intermittent over 30 minutes) with stratification based on the beta-lactam prescribed (cefepime, meropenem, or piperacillin/tazobactam)
Study NCT06116357 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: External Ultrasonic Micro-bubble
Description: The enrollmented hypertensive patients should aceepted CB modulation therapy by external ultrasonic micro-bubble
Study NCT04828993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis meglumine
Description: Tafamidis meglumine 20 mg, once daily, oral administration, for 72 weeks (18 months).
Study NCT05030207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-time Gated 4DCT
Description: Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
Study NCT05030207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional 4DCT
Description: Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
Study NCT06519812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Intrarenal Surgery and percutaneous nephrolithotomy
Description: A study was conducted to compare endoscopic combined intrarenal surgery and percutaneous nephrolithotomy as modalities of treatment for staghorn stones.
Study NCT04807933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate variability Biofeedback [HRV-BFB]
Description: BFB consists of a physiological recording used as a visual physiological feedback that can teach us how to control our physiology, which is naturally unconscious and uncontrollable. The BFB focused on the heart rate variability (HRV-BFB) could regulate the autonomic nervous system (vagal tone and sympathetic-parasympathetic balance) and the emotional state. The HRV BFB has received several clinical and experimental confirmations as a physiological remediation method. It is an innovative and non-pharmacological therapy frequently used to relieve stress.
Study NCT05956899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia
Study NCT05956899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: IV ondansetron 0.15mg/kg at the start of wound closure
Study NCT06137586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of GIP[1-42], GIP[1-30] or placebo
Description: This is a single arm study. All participants will go through all five experimental days in a randomized order. The interventions are A) 4pmol/kg/min GIP\[1-42\] B) 8pmol/kg/min GIP\[1-42\] C) 4pmol/kg/min GIP\[1-30\] D) 8pmol/kg/min GIP\[1-30\] E) Saline (placebo)
Study NCT04642391 — intervention group
Intervention type: DRUG
Intervention: Cosyntropin
Description: Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
Study NCT04150419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3 (control group)
Description: Neutral attentional training (control group).
Study NCT04486378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457 intravenous (IV)
Description: RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
Study NCT04486378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational group (no intervention)
Description: watchful waiting
Study NCT05789394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adipose-derived Mesenchymal Stem Cells
Description: Receive IT
Study NCT05789394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT05789394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: Undergo craniotomy
Study NCT05789394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05789394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir Tap
Description: Undergo Ommaya reservoir placement for collection of CSF
Study NCT05952570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral protein nutritional supplement (Fresubin protein powder)
Description: 50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months
Study NCT05952570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine nutrition regimen
Description: 50 patients will receive a routine nutrition regimen for 3 months. (control group)
Study NCT06010342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL118 Capsule
Description: Oral administration
Study NCT05897411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmasking previous conditioning procedure
Description: An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will be provided.
Study NCT05897411 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No unmasking of previous conditioning
Description: An explanation of the method for aversive conditioning of the comfort meal (masked administration of the meal with a high fat supplement) will not be provided.
Study NCT05733052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyester suture
Description: A No2 polyester suture will be used for tying special anatomical structures fr telieving the symptom. of stress urinary incontinence
Study NCT05609435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REASSURE
Description: REASSURE is comprised of three components that are intended to be integrated into survivorship care at each follow-up visit: 1) An online patient-reported outcome (PRO) assessment to comprehensively evaluate survivors' symptoms and concerns; 2) A tailored follow-up recommendation based on pre-established thresholds for reported symptoms and concerns. Survivors who report symptoms or concerns have a follow-up visit to discuss findings whereas survivors without symptoms or concerns will avoid a follow-up visit; and 3) Online survivorship messaging sent after the visit, which includes reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps survivors can take to reduce cancer risk.
Study NCT04451499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: The study specific smartphone app site will be based on current literature plus investigators experience and will include a wide knowledge on types of surgeries, dietary guidelines pre- and post-surgery, fluids type and amount, knowledge on supplementation use pre and post-surgery, general dietary knowledge, psychological information, physical activity, recommendation and tips for long-term surgery success, emphasis will be made on long-term follow-up meetings with the bariatric team and practical information on the preparation to the hospitalization process. The smartphone app site will contain video-based modules and encouraging messages. Patients will be encouraged to use the platform to ask questions and receive answers regarding any aspect of the surgery.
Study NCT05881161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence self-efficacy-enhancing exercise
Description: This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
Study NCT05881161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med-Stress Student
Description: Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
Study NCT05881161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med-Stress Student
Description: Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
Study NCT05142553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine HIPRA
Description: Subjects will receive one injection of COVID-19 Vaccine HIPRA
Study NCT05142553 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cominarty (Pfizer-BioNtech)
Description: Subjects will receive one injection of Cominarty Vaccine
Study NCT06127589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cessation advice (AWARD)
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
Study NCT06127589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cessation advice (AWARD)
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refuse to set a quit date).
Study NCT06127589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 1-week sampling of Nicotine Replacement Therapy (NRT) will be provided to support quit attempt. Full pharmacological treatment (12-week) will be available if needed.
Study NCT06127589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant messaging Support (IM)
Description: Chat-based mHealth personalized psychosocial and behavioural counselling (smoking cessation and SHS exposure reduction messages will be derived from previously tested interventional studies) using baseline children health and biofeedback data to support quitting throughout the intervention period of 3 months.